In 1976, countries in Africa including Zaire, now known as the Democratic Republic of Congo, and Sudan, which is present-day South Sudan, experienced almost identically timed outbreaks of a fatal virus. One of the viruses is what we have come to recognize as Ebola disease (EBOD).
Yet, given Ebola’s high fatality rate and its repeated emergence over decades, why hasn’t it been permanently eradicated? What factors contribute to its continuous appearance?
The answer to this isn’t as simple as the question asked. Although Ebola emerges from animal to human transference and spreads through intimate contact, these biological facts do not fully explain its persistence. The recurring quality also indicates a broader governance failure. Regional governments often lack the capacity to detect and contain cases early, while global institutions have repeatedly responded too slowly to prevent localized outbreaks from escalating. Hence, Ebola becomes less a purely biomedical problem and more a reflection of international investments.
While the persistence of Ebola cannot be attributed solely to its biological characteristics, understanding these characteristics is still important for analyzing the factors that shape its transmission and recurrence. Since its first appearance, the virus has led to sporadic, isolated outbreaks between 1994 to 2026. Ebola is classified as a zoonotic disease due to hunting, handling, and consumption of wild animals, which are believed to be the main causes of transmission. Between humans, direct contact with infected bodily fluids continues this, and when combined with the virus’s high viral load in late stages of affliction, makes it difficult to control without early detection or strict containment measures. Victims of EBOD will experience severe symptoms after about a week of incubation, most commonly high fever, vomiting, diarrhea, and hemorrhaging, with death generally ensuing a few days after. The average fatality rates sit at ~50%, but vary from 25%-90%, with smaller and more remote communities being disproportionately affected in Western and Central parts of the African continent.
During outbreaks, support often comes after the disease has been widely spread, when hospitals are overwhelmed and public trust is fragile. Instead of building resilient health systems before crises begin, much aid has been organized around short-term emergency intervention. That approach may help in the immediate moment, but it leaves the underlying structural vulnerability ever-present. Once attention moves elsewhere, the same weaknesses remain in place for another outbreak.
The most recent epidemic in May 2026 revealed that the problem is not only the virus itself, but the flawed aid system meant to contain it. The outbreak in the Democratic Republic of the Congo spread into Uganda, with WHO warning of a rapidly evolving emergency, while authorities and aid agencies scrambled to scale up diagnostics, contact tracing, and community outreach. By late May, WHO had already delivered more than 2,000 diagnostic test kits and was working on screening at transport hubs and water systems at treatment centers, which suggests that core response capacity was being built only after the outbreak was already well underway.
The clearest evidence of aid failure is that the response was delayed, uneven, and forced into emergency mode. A French report on the outbreak argued that sharp cuts in Western aid weakened surveillance systems; Africa CDC’s director said the loss of funding damaged the epidemiological surveillance chain such that the organization had lost about 37% of its funds. This matters because the outbreak was not uncontrolled despite a lack of knowledge about Ebola; it was uncontrolled because the systems that detect and interrupt transmission had been weakened before the crisis accelerated.
This pattern also shows how international aid often arrives too late to prevent escalation. The EU announced €15 million in humanitarian assistance only after the outbreak was already active, and the money was split between emergency operations, preparedness, and prevention. This directly exemplifies how response and prevention are being combined after the fact rather than sustained beforehand. Canada also announced $8 million in support for WHO, Africa CDC, the Red Cross, and NGOs, again underscoring that outside help was mobilized reactively once the outbreak had become a visible regional problem.
A stronger argument, then, is that Ebola reveals not just the presence of a dangerous disease, but the limits of an aid architecture that is episodic, reactive, and vulnerable to political budget cuts. Doctors Without Borders characterized an outbreak circulating undetected for weeks or months as a result of a slow and derisory international response, which is especially relevant here because the 2026 response was built around catching up after delay rather than preventing that delay in the first place. The pattern is clear: cuts to aid can weaken disease surveillance, making it more difficult to identify outbreaks early, causing them to spread, which increases the likelihood of international agencies only intervening after the crisis has escalated.
So, the 2026 outbreak supports a clearer conclusion; Ebola persists partly because international aid is not designed as durable prevention. It is often treated as an emergency charity instead of a long-term public health obligation, which is why the outbreak is best understood as a governance failure, not just a medical one.
Annika Paul is entering her second year at McGill University, currently pursuing a B.A. in Political Science and a minor in Economics. She is thoroughly fascinated with many aspects of the current political landscape, with a special focus on global health, international economic policy, and humanitarian aid.